SPI Infoamtion

このレポートは章ごとの個別販売も行っておりますのでお問い合わせ下さい。
※全てPDFでの販売となります。

Chapter- 1: INTRODUCTION -- Complimentary
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGY AND INFORMATION SOURCES
RELATED REPORTS
BCC ONLINE SERVICES
DISCLAIMER

Chapter-2: SUMMARY
SUMMARY TABLE GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, THROUGH 2015 ($ MILLIONS)
SUMMARY FIGURE GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, 2007-2015 ($ MILLIONS)

Chapter-3: OVERVIEW
CURRENT STATE OF CARDIOVASCULAR DISEASE
FIGURE 1 LEADING CAUSES OF DEATH IN THE UNITED STATES; 2006 (DEATHS PER 100,000)
ESTABLISHED DRUG CLASSES IN CARDIOVASCULAR DISEASE
Statins
Angiotensin Receptor Blocker
Angiotensin Converting Enzyme (ACE) inhibitors
EMERGING DRUG CLASSES
P2Y12 Inhibitors and Antagonists
Factor Xa Inhibitors
Cholesterol-Ester Transfer Protein (CETP) Inhibitor
TABLE 1 CETP INHIBITORS IN ACTIVE DEVELOPMENT
KEY RECENT EVENTS IN THE CARDIOVASCULAR MARKET
PLAVIX METABOLIZER 2C19 TRIGGERS U.S. WARNING
VALTURNA IS FIRST TO RECEIVE U.S. APPROVAL AS COMBINATION THERAPY FOR HYPERTENSION
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT
TABLE 2 RECENTLY APPROVED DRUGS
TABLE 3 SUMMARY PIPELINE FORECAST

Chapter-4: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS
INDUSTRY STRUCTURE
TABLE 4 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTH AND SHARE, THROUGH 2010 ($ MILLIONS)
MARKET CONCENTRATION AND PRICE SENSITIVITY
TABLE 5 COMPANY BY DISEASE CLASS, 2010 REVENUE ($ MILLIONS)
MARKET TRENDS
Overall Market Flat: Higher Mix of Generics Offset by Higher Volume
TABLE 6 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS ($ MILLIONS)
Massive Patent Expiration is a Growth Opportunity for Generics
Market Expansion via Disease Prevention is the Future of Cardio Care
Atrial Fibrillation is a Large and Emerging Disease State
Combination Therapies are Synergistic Revenue Generators
TABLE 7 COMPANY BY DISEASE CLASS, 2015 REVENUE ($ MILLIONS)
TABLE 8 MARKET SHARE BY LEADING CARDIOVASCULAR PLAYERS ($ MILLIONS)
TABLE 9 LARGEST REVENUE GENERATING THERAPIES IN THE CARDIOVASCULAR SEGMENT, 2009 AND 2010 ($ MILLIONS)

Chapter-5: MARKETS BY DISEASE
SUMMARY OF MARKET DYNAMICS
TABLE 10 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, THROUGH 2015 ($ MILLIONS)
HYPERTENSION
PATHOPHYSIOLOGY AND PATHOGENESIS
TABLE 11 HYPERTENSION STAGES AS MEASURED BY PRESSURE DIFFERENTIAL AT THE HEART (MMHG AND KILO-PASCAL)
TREATMENT AND MANAGEMENT
TABLE 12 CURRENT GLOBAL HYPERTENSION MARKET, 2007-2010 ($ MILLIONS)
Diovan/Co-Diovan
Micardis
Benicar
Norvasc
Cozaar/Hyzaar
TABLE 13 GLOBAL HYPERTENSION MARKET FORECAST, THROUGH 2015 ($ MILLIONS)
TABLE 14 FORECAST EPIDEMIOLOGY: HYPERTENSION
HYPERLIPIDEMIA
PATHOPHYSIOLOGY AND PATHOGENESIS
Genetic Factors in Hyperlipidemia
TABLE 15 GENERAL CLASSIFICATION OF HYPERLIPIDEMIA (TRIGLYCERIDE AND TOTAL CHOLESTEROL)
TABLE 16 FREDRICKSON CLASSIFICATION OF HYPERLIPIDEMIAS
TREATMENT AND MANAGEMENT
TABLE 17 CURRENT GLOBAL HYPERLIPIDEMIA MARKET, 2007-2010 ($ MILLIONS)
Lipitor
Crestor
Zetia
Vytorin
TABLE 18 GLOBAL HYPERLIPIDEMIA MARKET FORECAST, THROUGH 2015 ($ MILLIONS)
TABLE 19 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA
THROMBOSIS
PATHOPHYSIOLOGY AND PATHOGENESIS
TABLE 20 CURRENT GLOBAL THROMBOSIS MARKET, 2007-2010 ($ MILLIONS)
TREATMENT AND MANAGEMENT
Plavix
Lovenox
TABLE 21 GLOBAL THROMBOSIS MARKET FORECAST, THROUGH 2015 ($ MILLIONS)
CARDIAC FAILURE DISEASE
PATHOPHYSIOLOGY AND PATHOGENESIS
Stroke
TABLE 22 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
Cardiac Arrhythmias
Angina Pectoris
Myocardial Infarction (MI)
Congestive Heart Failure (CHF)
Acute Coronary Syndrome (ACS)
TABLE 23 CURRENT GLOBAL CARDIAC FAILURE MARKET, 2007-2010 ($ MILLIONS)
TREATMENT AND MANAGEMENT
Vastarel
Other Drugs
TABLE 24 GLOBAL CARDIAC FAILURE MARKET FORECAST, THROUGH 2015 ($ MILLIONS)
OTHER CARDIOVASCULAR DISEASE
PATHOPHYSIOLOGY AND PATHOGENESIS
Pulmonary Hypertension
Peripheral Artery Disease (PAD)
TABLE 25 OTHER CARDIOVASCULAR DISEASE CURRENT GLOBAL MARKET ($ MILLIONS)
TREATMENT AND MANAGEMENT
Tracleer
Other Drugs
TABLE 26 OTHER CARDIOVASCULAR GLOBAL MARKET FORECAST, THROUGH 2015 ($ MILLIONS)

Chapter-6: MARKETS BY DRUG CLASS
SUMMARY OF MARKET DYNAMICS
TABLE 27 CURRENT CARDIOVASCULAR MARKET BY DRUG CLASS, 2008-2010 ($ MILLIONS)
TABLE 28 CARDIOVASCULAR MARKET FORECAST BY DRUG CLASS, THROUGH 2015 ($ MILLIONS)
MONOTHERAPIES
STATINS
TABLE 29 STATIN CURRENT MARKET GROWTH AND SHARE, 2007-2010 ($ MILLIONS)
Genetic Influences to Statin Efficacy
TABLE 30 STATIN DRUG DOSING AND LDL REDUCTION CORRELATION
TABLE 31 STATIN MARKET FORECAST FOR HYPER-LIPIDEMIA, THROUGH 2015 ($ MILLIONS)
ANGIOTENSIN RECEPTOR BLOCKER (ARB)
TABLE 32 COMPARISON OF ARB PHARMACOKINETICS
TABLE 33 ARB CURRENT MARKET FOR HYPERTYENSION, GROWTH AND SHARE, 2007-2010 ($ MILLIONS)
Myocardial Infarction Risk Due to ARB Inhibition
ARB Impact on Alzheimer’s Disease Risk
TABLE 34 ARB MARKET FORECAST FOR HYPERTENSION, THROUGH 2015 ($ MILLIONS)
CALCIUM CHANNEL BLOCKERS (CCB)
TABLE 35 CCB CURRENT MARKET FOR HYPERTENSION, GROWTH AND SHARE, 2007-2010 ($ MILLIONS)
TABLE 36 CCB MARKET FORECAST FOR HYPERTENSION, THROUGH 2015 ($ MILLIONS)
LOW MOLECULAR WEIGHT HEPARINS (LMWH)
TABLE 37 LMWH CURRENT MARKET FOR THROMBOSIS, GROWTH AND SHARE, 2007-2010 ($ MILLIONS)
TABLE 38 LMWH MARKET FOR THROMBOSIS, FORECAST, THROUGH 2015 ($ MILLIONS)
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS
TABLE 39 ACE INHIBITORS FOR HYPERTENSION, GOWTH AND SHARE, 2007-2010 ($ MILLIONS)
TABLE 40 ACE INHIBITOR MARKET FORECAST FOR HYPERTENSION, THROUGH 2015 ($ MILLIONS)
P2Y12 AND FACTOR XA INHIBITORS
Effient (Prasugrel): a Leading P2Y12 Antagonist
TABLE 41 P2Y12 CURRENT MARKET GROWTH AND SHARE, 2007-2010 ($ MILLIONS)
TABLE 42 PY12 MARKET FORECAST, THROUGH 2015 ($ MILLIONS)
TABLE 43 FACTOR XA CURRENT THROMBOIS MARKET GROWTH AND SHARE, 2007-2010 ($ MILLIONS)
TABLE 44 FACTOR XA MARKET FORECAST, THROUGH 2015 ($ MILLIONS)
COMBINATION DRUG CLASSES

Chapter-7: MARKETS BY GEOGRAPHY
SUMMARY
TABLE 45 CURRENT MARKET SIZE BY GEOGRAPHY, 2009 AND 2010 ($ MILLIONS)
METHODOLOGY
TABLE 46 MARKET FORECAST BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS)
UNITED STATES
TABLE 47 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (U.S.)
TABLE 48 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (U.S.)
TABLE 49 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (U.S.)
WESTERN EUROPE
TABLE 50 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (WESTERN EUROPE)
TABLE 51 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (WESTERN EUROPE)
TABLE 52 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (WESTERN EUROPE)
JAPAN
TABLE 53 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (JAPAN)
TABLE 54 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (JAPAN)
TABLE 55 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (JAPAN)
STRATEGIES TO ACCESS EMERGING MARKETS
EMERGING MARKETS FORECAST
BRAZIL
MARKET OVERVIEW
REGULATORY CONSIDERATIONS
PATENT CONSIDERATIONS
TABLE 56 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (BRAZIL)
TABLE 57 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (BRAZIL)
TABLE 58 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (BRAZIL)
CHINA
MARKET OVERVIEW
REGULATORY CONSIDERATIONS
PATENT CONSIDERATIONS
TABLE 59 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (CHINA)
TABLE 60 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (CHINA)
TABLE 61 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (CHINA)
INDIA
MARKET OVERVIEW
REGULATORY CONSIDERATIONS
PATENT CONSIDERATIONS
TABLE 62 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (INDIA)
TABLE 63 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (INDIA)
TABLE 64 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (INDIA)
RUSSIA
MARKET OVERVIEW
REGULATORY CONSIDERATIONS
PATENT CONSIDERATIONS
TABLE 65 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (RUSSIA)
TABLE 66 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (RUSSIA)
TABLE 67 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (RUSSIA)
SOUTH AMERICA
TABLE 68 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (SOUTH AMERICA)
TABLE 69 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (SOUTH AMERICA)
TABLE 70 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (SOUTH AMERICA)
CARRIBEAN
TABLE 71 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (CARRIBEAN)
TABLE 72 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (CARRIBEAN)
TABLE 73 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (CARRIBEAN)
NORTHERN EUROPE
TABLE 74 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (NORTHERN EUROPE)
TABLE 75 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (NORTHERN EUROPE)
TABLE 76 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (NORTHERN EUROPE)
CENTRAL AND EASTERN EUROPE
TABLE 77 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (CENTRAL & EASTERN EUROPE)
TABLE 78 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (CENTRAL & EASTERN EUROPE)
TABLE 79 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (CENTRAL & EASTERN EUROPE)
AUSTRALIA
TABLE 80 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (AUSTRALIA)
TABLE 81 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (AUSTRALIA)
TABLE 82 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (AUSTRALIA)
ASIA-OTHER
TABLE 83 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (ASIA-OTHER)
TABLE 84 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (ASIA-OTHER)
TABLE 85 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (ASIA-OTHER)
MIDDLE EAST
TABLE 86 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (MIDDLE EAST)
TABLE 87 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (MIDDLE EAST)
TABLE 88 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (MIDDLE EAST)
SOUTHERN AFRICA
TABLE 89 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (SOUTHERN AFRICA)
TABLE 90 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (SOUTHERN AFRICA)
TABLE 91 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (SOUTHERN AFRICA)
AFRICAN REGIONS EXCLUDED FROM EPIDEMIOLOGY FORECAST

Chapter-8: PIPELINE ANALYSIS
TABLE 92 APPROVED PRODUCT FORECAST, 2010 AND 2015 ($ MILLIONS)
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT
VALTURNA IS FIRST TO RECEIVE U.S. APPROVAL AS COMBINATION THERAPY FOR HYPERTENTION
ANTICOAGULANTS ENABLE NEW PRODUCT APPROVALS, IN PARTICULAR FACTOR XA
P2Y12 IS A PROVEN TARGET FOR MULTIPLE INDICATIONS; APPROVALS ARE EXPECTED
APOB-100 AS A NOVEL TREATMENT FOR HYPERLIPIDEMIA
INCREASED DRIVE TO ESTABLISH AND EXTEND HIGH HDL CHOLESTEROL LEVELS
2009 APPROVALS IN CARDIOVASCULAR THERAPY
MULTAQ (DRONEDARONE) -- SANOFI-AVENTIS
TABLE 93 MULTAQ SNAPSHOT
XARELTO (RIVAROXABAN) -- BAYER SCHERING/J&J
TABLE 94 XARELTO SNAPSHOT
EFFIENT/EFIENT (PRASUGREL) -- ELI LILLY/DAIICHI SANKYO
TABLE 95 EFFIENT SNAPSHOT
RENDIX (DABIGATRAN) -- BOEHRINGER INGELHEIM
TABLE 96 RENDIX SNAPSHOT
RECENTLY FILED/PRE-REGISTRATION COMPOUNDS
APIXABAN -- BRISTOL-MYERS SQUIBB (BMS)/PFIZER
TABLE 97 APIXABAN SNAPSHOT
BRILINTA (TICAGRELOR/AZD6140) -- ASTRAZENECA
TABLE 98 BRILINTA SNAPSHOT
CERTRIAD (ROSUVASTATIN/ FENOFIBRIC ACID) -- ASTRAZENECA/ABBOTT
TABLE 99 CERTRIAD SNAPSHOT
PHASE II/III COMPOUNDS
LCZ696 -- NOVARTIS
TABLE 100 LCZ696 SNAPSHOT
EDOXABAN (DU-176B) -- DAIICHI SANKYO
TABLE 101 EDOXABAN (DU-176B) SNAPSHOT
SCH 530348 -- MERCK
TABLE 102 SCH530348 SNAPSHOT
TYRISA/DARAPLADIB -- GSK
TABLE 103 TYRISA SNAPSHOT
BETRIXABAN -- PORTOLA/MERCK
TABLE 104 BETRIXABAN SNAPSHOT
PIPELINE ANALYSIS BY COMPANY
TABLE 105 PFIZER’S CARDIOVASCULAR PIPELINE
TABLE 106 SANOFI-AVENTIS’ CARDIOVASCULAR PIPELINE
TABLE 107 NOVARTIS’ CARDIOVASCULAR PIPELINE
TABLE 108 MERCK’S CARDIOVASCULAR PIPELINE
TABLE 109 BMS’ CARDIOVASCULAR PIPELINE
TABLE 110 ASTRA-ZENECA’S CARDIOVASCULAR PIPELINE

Chapter-9: COMPANY PROFILES
SUMMARY
TABLE 111 COMPANY REVENUE AND MARKET SHARE ANALYSIS, 2007-2009 ($ MILLIONS)
TABLE 112 MARKET FORECAST BY COMPANY, THROUGH 2015 ($ MILLIONS)
ABBOTT LABORATORIES
Business Overview
Corporate Strategy
ACTELION LTD.
Business Overview
Leading Products
Corporate Strategy
ASTELLAS PHARMA, INC.
Business Overview
Leading Products
Corporate Strategy
ASTRAZENECA
Business Overview
Leading Products
Crestor
Atacand
Certriad
Corporate Strategy
BAYER AG
Business Overview
Leading Products
Adalat
BRISTOL-MYERS SQUIBB COMPANY
Business Overview
Leading Products
Plavix
Apixaban
Corporate Strategy
DAIICHI SANKYO, INC. (DAIICHI SANKYO GROUP)
Business Overview
Leading Products
Benicar
Effient
Corporate Strategy
ELI LILLY & CO.
Business Overview
Leading Products
FOREST LABORATORIES, INC.
Business Overview
Leading Products
Benicar
Corporate Strategy
GILEAD SCIENCES, INC.
Business Overview
Leading Products
Corporate Strategy
GLAXOSMITHKLINE (GSK)
Business Overview
Leading Products
Arixtra
Corporate Strategy
MERCK & CO., INC.
Business Overview
Leading Products
Vytorin
Zetia
Cozaar
Hyzaar
Zocor
Corporate Strategy
MYLAN, INC.
Business Overview
Corporate Strategy
NOVARTIS
Business Overview
Leading Products
Diovan
Co-Diovan
Exforge
Corporate Strategy
PFIZER, INC.
Business Overview
Leading Products
Lipitor
Norvasc
Revatio
Corporate Strategy
SANOFI AVENTIS
Business Overview
Leading Products
Plavix
Lovenox
Multaq
Corporate Strategy
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Business Overview
Leading Products
Blopress
Atacand and Atacand Plus
Corporate Strategy
TEVA PHARMACEUTICAL INDUSTRIES LTD
Business Overview
Leading Products
Clopidogrel
Corporate Strategy
THE MEDICINES COMPANY, INC.
Website: www.themedicinescompany.com
Business Overview
Leading Products
Angiomax
Corporate Strategy
UNITED THERAPEUTICS CORPORATION
Business Overview
Leading Products
Remodulin
Corporate Strategy